Developed by a research team led by Xiamen University, the kit can be used for clinical cases, suspected cases and the screening of high-risk groups, improving the testing efficiency of front-line medical institutions.
The kit had conducted clinical trials in hospitals in Wuhan, the epicentre of the virus outbreak. The combination of nucleic acid tests and antibody detection has improved the detection rate.
According to the developer, three antibody reagents for Covid-19 have been approved by the European Union and exported to countries including Italy, Austria and the Netherlands. — Xinhua